NCT06310057View on ClinicalTrials.gov

Tofacitinib in the Treatment of Refractory Axial Spondyloarthritis Patients: A Dose Escalation Study

PHASE4CompletedINTERVENTIONAL
Enrollment

92

Participants

Timeline

Start Date

January 1, 2022

Primary Completion Date

March 1, 2024

Study Completion Date

March 1, 2024

Conditions
Axial Spondyloarthritis
Interventions
DRUG

Tofacitinib

Tofacitinib (JAKi) is a targeted therapy option for patients with refractory ax-SpA.

Trial Locations (1)

1000

Bangabandhu Sheikh Mujib Medical University, Dhaka

Sponsors
All Listed Sponsors
collaborator

Incepta Pharmaceuticals Ltd

INDUSTRY

lead

Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh

OTHER

NCT06310057 - Tofacitinib in the Treatment of Refractory Axial Spondyloarthritis Patients: A Dose Escalation Study | Biotech Hunter | Biotech Hunter